Early studies suggest that this peptide – a dual agonist of incretin and GIP receptors – may provide a substantial improvement in weight management programs . Beyond existing therapies, this dual-action compound seems to affect hunger and calorie burn by means of distinct pathways . Although further investigation is needed , current data raise